Projects

1 - 10 of 18 results

Sorteren op
Search term:

SRP-Groeifinanciering: Single-domain antibody fragment (SdAb)-based TArgeted Radionuclide Therapy: STaRT programme Vrije Universiteit Brussel

Clinical sciences, Supporting clinical sciences
The Strategic Research Programme - Growth - SdAb-based Targeted Radionuclide Therapy (STaRT) brings together a unique group of experts that aims to conduct a patient-focused STaRT programme with the potential of clinical translation in the next 5 years. The consortium intents to preclinically validate and translate into the clinic a single-domain antibody fragment (sdAb)-based platform as a tool for targeted radionuclide therapy (TRNT) of ...

Perturbation of apolipoprotein E4 (apoE4) activity in AD pathology using single domain antibodies and targeting them to the brain Ghent University

Jan Gettemans
Department of Biomolecular Medicine, Department of Pharmaceutics

The APOE-ε4 allele is the most prominent genetic risk factor for late onset AD. We will use ApoE4 nanobodies to stabilize the non-pathological conformation of ApoE4, and use photoporation as a means of introducing nanobodies in mammalian cells. In addition, we plan to target nanobodies to the brain in collaboration with prof. Breakefield (Dept. Neurology, Harvard Medical School, Boston).

Nanobodies in Health : Next generation Antibody fragments for Medical Applications Vrije Universiteit Brussel

Department of Bio-engineering Sciences
Naturally occurring camelid Heavy-chain antibodies have evolved to be fully functional in the absence of a light chain. In a previous VUB-funded GOA project, a network consisting of the research groups of S. Muyldermans, J. Steyaert and P. De Baetselier has built on fundamental research into the properties of Heavy-chain antibodies to develop medical applications of Heavy chain antibody-derived single-domain antibody fragments referred to as ...

New antivirals against human parainfluenza virus Ghent University

Xavier Saelens
Department of Biochemistry and microbiology, Department of Pharmaceutics

Human parainfluenza viruses (hPIVs) are a major cause of severe respiratory disease in (very) young children and the immunocompromised. hPIVs are the second main cause of hospitalization due to acute respiratory tract infection in children under five (respiratory syncytial virus ranks first). There are no clinically approved vaccines or antivirals available against hPIVs to prevent or treat these infections. Our group recently isolated ...

IOF Accelerator: “FLT imaging using Nanobodies: effective tool for life sciences and medical applications (NLITE) Vrije Universiteit Brussel

Electronics and Informatics, Supporting clinical sciences
The IOF GEAR NLITE is an interdisciplinary consortium that aims to advance novel technologies for image-guided surgery into clinical applications. Part of the research is dedicated to the development of single-domain antibody (sdAb)-based contrast agents that specifically bind to cancer-associated protein markers for pre- and/or intraoperative visualization of cancerous tissue. We now have identified a clear unmet clinical need for colorectal ...

IOF Accelerator: Camelidae-derived single domain antibody fragments for theranosis of cancer Vrije Universiteit Brussel

Supporting clinical sciences
The accelerator budget will be invested in the development of an automated synthesis procedure for 18F labeled sdAbs in a GMP compliant procedure to allow clinical trials using PET/CT. At VUB we develop a pipeline of sdAb based diagnostics for imaging cancer cells and immune cell in the tumor microenvironment. The investment will accelerate the clinical translation of these imaging drugs.

New and innovative antimicrobial solutions against microbial biofilms and fungal infections, with applications in the medical and agrochemical domain KU Leuven

Bruno Cammue
Surface and Interface Engineered Materials (SIEM), Molecular Biotechnology of Plants and Micro-organisms, Microbial and Plant Genetics (CMPG), Laboratory for Clinical Infectious and Inflammatory Disorders

The primary aim of this IOF mandate is the identification of novel antifungal and/or antibiofilm molecules. Focus is on novel molecules or combinations of molecules that are effective against resistant fungi and/or fungal biofilms; and on the unraveling of their mode of action. This research forms the basis for valorisation in the following domains (i) treatment/control of fungal infections in human, animal, and plant context; as well as (ii) ...

Aggregation as a mechanism for p53 oncogenic transformation: clinical relevance and new tools for its study KU Leuven

Joost Schymkowitz
Switch Laboratory (VIB-KU Leuven), Translational Cell & Tissue Research

The p53 tumor suppressor is one of the most frequently mutated genes in human cancers, up to 50% of all cancers. This event has three different consequences: (i) Loss-of- function, (ii) Dominant-negative activity, i.e. reduced amount of active p53 due to the incorporation of wild-type and mutant monomers into the mixed tetramer, and (iii) Gain-of-function, that is, the ability of mutant p53 to interact with other proteins and inactivate them. ...